Compare Stocks: VOR, DNTH, EWTX, and TNGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$79.34 -2.7%	$102.17	$32.22 ▼ $117.88	$4.37B	1.35	923,509 shs	68,707 shs
EWTX Edgewise Therapeutics	$37.68 -2.0%	$42.86	$14.25 ▼ $48.51	$4.09B	0.35	1.24 million shs	109,032 shs
TNGX Tango Therapeutics	$23.25 -3.8%	$24.37	$6.69 ▼ $34.39	$3.93B	1.17	3.38 million shs	440,191 shs
VOR Vor Biopharma	$19.67 -0.7%	$21.91	$6.50 ▼ $33.42	$1.17B	1.78	1.06 million shs	140,559 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	-0.97%	-7.35%	-23.19%	-19.46%	+136.71%
EWTX Edgewise Therapeutics	-1.56%	-4.59%	-13.40%	-3.22%	+154.47%
TNGX Tango Therapeutics	+1.51%	+4.72%	+1.64%	-18.48%	+238.52%
VOR Vor Biopharma	-0.50%	+6.57%	-11.21%	+7.03%	-36.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$79.34 -2.7%	$102.17	$32.22 ▼ $117.88	$4.37B	1.35	923,509 shs	68,707 shs
EWTX Edgewise Therapeutics	$37.68 -2.0%	$42.86	$14.25 ▼ $48.51	$4.09B	0.35	1.24 million shs	109,032 shs
TNGX Tango Therapeutics	$23.25 -3.8%	$24.37	$6.69 ▼ $34.39	$3.93B	1.17	3.38 million shs	440,191 shs
VOR Vor Biopharma	$19.67 -0.7%	$21.91	$6.50 ▼ $33.42	$1.17B	1.78	1.06 million shs	140,559 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	-0.97%	-7.35%	-23.19%	-19.46%	+136.71%
EWTX Edgewise Therapeutics	-1.56%	-4.59%	-13.40%	-3.22%	+154.47%
TNGX Tango Therapeutics	+1.51%	+4.72%	+1.64%	-18.48%	+238.52%
VOR Vor Biopharma	-0.50%	+6.57%	-11.21%	+7.03%	-36.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$129.83	61.21% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$51.33	34.61% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	83.73% Upside
VOR Vor Biopharma	2.90	Moderate Buy	$41.71	111.03% Upside

Current Analyst Ratings Breakdown

Latest VOR, DNTH, EWTX, and TNGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$45.00 ➝ $57.00
9/14/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D+) ➝ Hold (C-)
9/11/2026	DNTH Dianthus Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$135.00
9/4/2026	DNTH Dianthus Therapeutics	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$156.00
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$66.00 ➝ $68.00
8/12/2026	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$32.00 ➝ $35.00
8/12/2026	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$18.00 ➝ $27.00
8/11/2026	TNGX Tango Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D-) ➝ Sell (D+)
8/11/2026	EWTX Edgewise Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$32.00 ➝ $36.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$2.04M	2,163.39	N/A	N/A	$11.41 per share	7.06
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
TNGX Tango Therapeutics	$53.81M	74.12	N/A	N/A	$2.57 per share	9.20
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VOR, DNTH, EWTX, and TNGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	DNTH Dianthus Therapeutics	-$0.9434	N/A	N/A	N/A	$0.44 million	N/A
11/5/2026	Q3 2026	EWTX Edgewise Therapeutics	-$0.5335	N/A	N/A	N/A	$129.17 million	N/A
11/3/2026	Q3 2026	TNGX Tango Therapeutics	-$0.3537	N/A	N/A	N/A	$3.28 million	N/A
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	26.10	26.10
EWTX Edgewise Therapeutics	N/A	16.24	16.24
TNGX Tango Therapeutics	N/A	50.82	50.82
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
EWTX Edgewise Therapeutics	N/A
TNGX Tango Therapeutics	78.99%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	3.02%
EWTX Edgewise Therapeutics	21.30%
TNGX Tango Therapeutics	6.50%
VOR Vor Biopharma	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	92	54.80 million	53.14 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable
VOR Vor Biopharma	76	59.16 million	59.00 million	N/A

VOR, DNTH, EWTX, and TNGX Headlines

Recent News About These Companies

Vor Biopharma (VOR) Could Be 52% Undervalued As Phase 3 gMG Data Draw Focus

October 9, 2026 | uk.finance.yahoo.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026 | globenewswire.com

Durable MG Responses From Telitacicept Could Be A Game Changer For Vor Biopharma (VOR)

October 4, 2026 | finance.yahoo.com

Vor Biopharma (NASDAQ:VOR) Stock Jumps 5.3% - Here's What Happened

September 30, 2026 | marketbeat.com

Vor Biopharma: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | finanznachrichten.de

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | marketscreener.comM

Vor Biopharma en hausse après la publication de résultats encourageants concernant un médicament contre les maladies auto-immunes

September 29, 2026 | boursorama.comB

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

September 29, 2026 | globenewswire.com

Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus

September 29, 2026 | theglobeandmail.com

Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Average Price Target of $41.71 According to Brokerages

September 28, 2026 | marketbeat.com

【VOR】Vor Biopharma

September 23, 2026 | note.comN

Vor Biopharma no fórum Stifel 2026: telitacicept aposta em dupla estratégia

September 23, 2026 | br.investing.com

Vor Biopharma在Stifel 2026论坛上阐述telitacicept双路径布局

September 23, 2026 | cn.investing.com

Vor Biopharma al forum Stifel 2026: telitacicept punta su doppia strategia

September 23, 2026 | it.investing.com

Vor Biopharma en foro Stifel 2026: telitacicept avanza en doble vía

September 23, 2026 | mx.investing.com

Vor Biopharma (NASDAQ:VOR) Shares Down 8.2% - Should You Sell?

September 23, 2026 | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Trading Up 6.1% - Still a Buy?

September 22, 2026 | marketbeat.com

Vor Biopharma: A Funded Replication Story With Franchise Potential

September 18, 2026 | seekingalpha.com

Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance

September 17, 2026 | finance.yahoo.com

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Vor Biopharma Completes Enrollment in Phase 3 Trial of Investigational Drug for Generalized Myasthenia Gravis

September 8, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VOR, DNTH, EWTX, and TNGX Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$79.34 -2.23 (-2.73%)

As of 11:21 AM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Edgewise Therapeutics NASDAQ:EWTX

$37.67 -0.78 (-2.02%)

As of 11:21 AM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Tango Therapeutics NASDAQ:TNGX

$23.25 -0.92 (-3.81%)

As of 11:21 AM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Vor Biopharma NASDAQ:VOR

$19.66 -0.14 (-0.68%)

As of 11:21 AM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VOR, DNTH, EWTX, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VOR, DNTH, EWTX, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VOR, DNTH, EWTX, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VOR, DNTH, EWTX, and TNGX Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Edgewise Therapeutics NASDAQ:EWTX

Tango Therapeutics NASDAQ:TNGX

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VOR, DNTH, EWTX, and TNGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VOR, DNTH, EWTX, and TNGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VOR, DNTH, EWTX, and TNGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VOR, DNTH, EWTX, and TNGX Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

Edgewise Therapeutics NASDAQ:EWTX

Tango Therapeutics NASDAQ:TNGX

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools